ALK V1180L

CI-VAR-00004437Explore in graph →NP_004295.2:p.Val1180LeuNM_004304.5:c.3538G>CClinVar 1705031 CIViC 528 rs2148166660

Curated evidence

Evidence by cancer (5 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–5 of 5 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma5
EML4::ALK Fusion AND ALK V1180L	Alectinib	Predictive	D	Supports Resistance	3	accepted	EID1286 The EML4 ALK variant 1 containing NSCLC cell line H3122 is highly sensitive to alectinib, and an alectinib resistant derivative cell line H3122 CHR-A1 was generated by incubation of H3122 in increasin… (full text at CIViC) PMID 25228534 · Katayama et al., 2014 · Open in CIViC	civic
EML4::ALK Fusion AND ALK V1180L	ALK Inhibitor TAE684	Predictive	D	Supports Sensitivity Response	3	accepted	EID1290 The V1180L mutation in the kinase domain of rearranged ALK was found in an alectinib resistant cell line named H3122 CHR-A1, which was derived from the alectinib sensitive EML4-ALK variant 1 containin… (full text at CIViC) PMID 25228534 · Katayama et al., 2014 · Open in CIViC

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
1705031	Likely pathogenic	no assertion criteria provided	0	Lung cancer	somatic	1	—	clinvar